Injection or operation — what actually drives the decision?

"Do I actually need an operation?" is the question most patients bring to their first consultation — and it is the right place to start. For many, the answer is no. Reaching that conclusion, though, requires a different framing of the choice.

The more useful question is not 'injection or surgery?' It is: does surgery add anything that an injection cannot already provide?

At MSK Doctors, that question is answered by MRI, not by a presumption toward theatre. When imaging confirms that a focal cartilage defect is suitable for a ChondroFiller® outpatient injection — a 30–45 minute appointment under ultrasound guidance, with no incision, no general anaesthetic, and no hospital admission — proceeding to an operation instead constitutes over-treatment. The clinical decision belongs to the scan, not to surgical convention.

Removing anaesthetic and surgical risk from the calculation changes the threshold for acting early. Patients who previously faced a prolonged holding pattern while their defect gradually worsened now have a realistic option to treat sooner, at substantially lower procedural risk.

The biology of repair is identical whichever route is used. ChondroFiller's collagen scaffold recruits the patient's own progenitor cells from the synovium and subchondral bone in exactly the same way whether the gel is placed under ultrasound guidance in a clinic room or delivered arthroscopically in theatre. What differs is procedure intensity — and whether that intensity is warranted for a given defect is a question a consultant-led MRI review answers case by case.

How ChondroFiller recruits your own cells as a scaffold

Articular cartilage presents a fundamental biological problem: it has no blood supply. Without vascularity, the repair signals and progenitor cells that heal most tissues after injury simply never arrive. Left alone, a focal cartilage defect does not close — it widens.

ChondroFiller addresses this directly, not by importing cells into the joint but by supplying the structural template that was missing. Placed under ultrasound guidance, the acellular collagen gel polymerises within 3–5 minutes, forming a 3D scaffold that integrates with the joint's natural fibrin. From that point, progenitor cells from the surrounding synovium and subchondral bone begin migrating into the matrix — drawn in by the scaffold architecture itself. This process, known as acellular matrix-induced chondrogenesis, requires no externally harvested or manipulated cells.

The recruitment is measurable, not theoretical. In an ex vivo osteochondral model using human femoral condyle tissue, the ChondroFiller group showed a 2.4-fold increase in DNA content by day 14 without any added cells — direct evidence of active endogenous cell ingress into the scaffold. That is a laboratory finding, not a clinical outcome promise, but it confirms the biological logic underlying the approach.

Over the following 12 months the defect progressively fills; by one to two years the scaffold has been completely resorbed and replaced by the patient's own tissue. The injection is, in that sense, a temporary scaffold for a permanent biological process.

Because the repair mechanism is driven entirely by the scaffold's architecture and the patient's own cells, it functions identically however the gel reaches the joint. The injection route does not dilute the biology — which is precisely why the injectable pathway offers genuine tissue support rather than temporary cushioning.

What the outpatient injection appointment actually involves

Once the gel has polymerised and the patient leaves the clinic, the most important practical instruction is also the one that surprises people most: protected weight-bearing for four to six weeks. This is not a surgical precaution — there is no wound to protect. It reflects the scaffold's early biomechanical state. A porcine in vitro loading study found that ChondroFiller could not immediately shield the opposing joint surface under cyclic load because the material requires time to stabilise within the defect. Controlled weight-bearing during that window allows secure integration before the joint is asked to work at full capacity.

The six-to-twelve-week window that follows is active rather than passive — physiotherapy to restore range of motion and progressive muscle loading begins once the scaffold is stable. Published knee series show that Lysholm and IKDC scores continue to improve through six months, with functional maturation largely complete by that point.

For comparison, the surgical alternative — keyhole arthroscopy to facilitate ACIC or AMIC for large, unstable focal defects — involves theatre admission, direct defect preparation under anaesthetic, a formal operative step, and a recovery pathway that follows the same post-procedure weight-bearing logic but with the added burden of the operative episode itself.

The injection pathway opens scaffold-based cartilage repair to patients for whom the procedural burden of surgery was previously a barrier — whether through anaesthetic risk, comorbidity, or personal preference — without compromising the underlying biological mechanism.

Who is suited to injection and who needs surgery

The practical question — injection or arthroscopic surgery — resolves into two patient profiles with distinct internal logic.

For many patients with focal cartilage defects, the injection pathway is the appropriate primary treatment. MRI confirmation that the defect is suitable for scaffold delivery is the decisive threshold: when imaging supports that assessment, the injection route holds regardless of the patient's age or defect size. Because the gel coats the whole cartilage surface and the protective work is done by the scaffold itself, there is no upper age ceiling and no defect-size limit that automatically redirects a patient toward theatre.

The counter-intuitive case is advanced osteoarthritis. Patients with Kellgren–Lawrence Grade III or IV joint degeneration might expect to be considered candidates only for replacement. In practice, the calculation runs the other way: at that level of wear, surgical reconstruction carries greater procedural risk and typically produces poorer outcomes than in focal, otherwise-healthy joints. The injection's top-down mechanical cushioning is precisely the approach that suits a heavily degenerated joint. Surgery is not the stronger option here — it is the less appropriate one.

Surgical escalation via keyhole arthroscopy is genuinely indicated for a distinct subset: large, localised, unstable Grade III–IV focal defects that cannot be adequately stabilised by injection alone and require direct defect preparation and joint drying to facilitate ACIC or AMIC under visual control.

That exclusion principle — advanced joint disease as a reason to favour injection over surgery — is supported by evidence from other joints. In a 26-patient hip arthroscopy cohort followed for up to five years, those with pre-existing Tönnis Grade 2–3 osteoarthritis had poor surgical outcomes, whereas patients with more focal lesions in otherwise-preserved joints fared substantially better. The joints differ in anatomy, but the candidacy logic carries across: where degeneration is global rather than focal, surgical scaffolding is less likely to succeed.

At MSK Doctors the pathway recommendation is imaging-led. A clinical MRI assessment identifies the defect's size, depth, location, and surrounding joint condition before any pathway decision is made — the scan informs the recommendation, not a default toward theatre or away from it.

What the clinical evidence shows — and where gaps remain

The strongest comparative data comes from a randomised controlled trial pitting ChondroFiller against microfracture in 23 patients with focal knee defects. IKDC scores in the ChondroFiller group improved significantly at three, six, and twelve months — and MRI showed good early defect filling with progressive maturation over that period. The microfracture arm, it should be noted, was substantially depleted by patient dropout: the high attrition rate in the surgical group is a methodological limitation that constrains head-to-head interpretation, even as it reflects real-world attitudes toward operative procedures.

A separate 12-month knee series (n=17, mean age 31) confirmed the trajectory of recovery. Lysholm and IKDC scores rose significantly at three and six months, then held steady between six and twelve months — indicating that the primary repair phase completes within roughly the first half-year rather than extending indefinitely.

For longer follow-up, a 26-patient hip arthroscopy cohort tracked for three to five years found that 17 of the 21 patients available at final review achieved good or excellent outcomes. Across the published ChondroFiller dataset the reported complaint rate is approximately 0.06%. A 2025 prospective wrist study (n=25 treated defects) extended scaffold feasibility to small joints, with significantly better Outerbridge and ICRS scores at follow-up arthroscopy versus untreated controls.

The existing data are encouraging but drawn from relatively small cohorts; long-term head-to-head evidence comparing injection and surgical delivery in the knee remains an open research question.

Combination therapy and how to take the next step

The CFI+ combination extends the non-surgical pathway to a patient profile that previously sat awkwardly between options: a joint that is both worn at the surface and chronically inflamed. For those patients, addressing cartilage loss alone often leaves the inflammatory environment — a driver of ongoing degeneration — untouched.

The two components work through distinct mechanisms and should not be treated as a single product. ChondroFiller provides the regenerative scaffold: the collagen matrix recruits progenitor cells to work on the damaged surface. Arthrosamid is a polyacrylamide hydrogel — a durable, non-regenerative cushion that integrates with the inner joint wall, reducing mechanical load and calming synovial inflammation. Both are delivered in a single clinic appointment, addressing the surface and the joint environment in parallel, without any operative step. The clinical rationale is straightforward: where degeneration and reactivity coexist, a strategy that targets only one may leave the other to progress.

A brief access note: ChondroFiller is available on a private basis only — it is not commissioned by the NHS, is not covered by private medical insurance, and is not FDA-approved in the United States. For patients in Lincolnshire and the wider non-London catchment, MSK Doctors consultants can assess suitability at Sleaford or Grantham without a GP referral and without NHS-style waiting. Appointments can be booked directly at mskdoctors.com.

1. [1] Ex vivo osteochondral biomimetic platform for cartilage regeneration — ChondroFiller group. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Implantation of ChondroFiller Liquid as a scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
4. [4] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60 month cohort study. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y